Role of slowly digestible starch in diabetes risk factors in pre-diabetic people
Role of slowly digestible starch in diabetes risk factors in pre-diabetic people
批准号:
8372789
负责人:
Eric Ravussin
金额:
$43.31万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2017-04-30
关键词:
AcetatesAgeAmylasesAmylopectinAmyloseBacterial GenesButyratesCaloric RestrictionCartoonsCoenzyme ACoenzyme A-TransferasesConsumptionDataDesire for foodDevelopmentDiabetes MellitusDietDietary InterventionDietary SupplementationDouble-Blind MethodEatingEndotoxemiaEnergy IntakeExerciseFatty acid glycerol estersFermentationHealthHormonesHumanImpaired fasting glycaemiaIncidenceIndividualInflammationIngestionInsulin ResistanceIntakeInterventionLarge IntestineLife StyleLipidsLiverMetabolicMuscleNon-Insulin-Dependent Diabetes MellitusObesityParticipantPhysical activityPlasmaPopulationPrediabetes syndromeProductionPropionatesRandomized Controlled Clinical TrialsRandomized Controlled TrialsRegimenRiskRisk FactorsRodentRoleSerum MarkersStarchStructure of beta Cell of isletSupplementationTestingVolatile Fatty AcidsWeightYogurtblood glucose regulationdiabetes riskdiabeticdisorder riskfeedingghrelinglucagon-like peptide 1gut microbiotahigh riskimpaired glucose toleranceimprovedinflammatory markerinsulin secretioninsulin sensitivitymicrobialmicrobial communityoxidationresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In this double-blind randomized controlled trial, 80 individuals (35-65y) with pre-diabetes (IGT/IFG) will receive either a diet containing slow digestible starch (amylose; N=40) or "control" starch (amylopectin; N=40) for 3 months. Our data in rodents (supported by others) have shown that the ingestion of slow digestible starch: a) enhances the gut microbial profile; b) reduces metabolic endotoxemia; c) increases fermentation and production of butyrate & propionate; d) increases beneficial gut hormones such as GLP-1 and PYY; e) lowers the glycemic load and; f) suppresses appetite Therefore, we propose to feed a slowly digestible starch to simultaneously target several mechanisms known to be important in glucose homeostasis with emphasis on insulin sensitivity, fat oxidation and ectopic fat. We will test the hypothesis that improved composition of the gut microbiota with a daily intake of 45 g of amylose for 3 months in individuals with IGT and/or IFG will in turn improve risk factors for the development of T2DM such as: a) enhancement of insulin sensitivity (FSIGTT; Aim1); b) decrease appetite and food intake (Aim2); c) decrease ectopic fat depots (1H-MRS; Aim1); d) decrease inflammation (serum markers; Aim1) and; e) modify the composition of large intestine microbiota in a metabolically favorable way (Aim3). This dietary intervention approach (addition of slowly digestible starch in yogurts) may prove more tolerable than daily caloric restriction and exercise and therefore more practically applicable for the treatment of T2DM.
PUBLIC HEALTH RELEVANCE: People with impaired glucose tolerance (IGT) suffer from insulin resistance and low grade inflammation and are at high risk of developing type 2 diabetes. Intensive lifestyle changes (reduced energy intake and increased physical activity) decrease the incidence of diabetes in people with IGT. However such lifestyle changes are difficult to maintain over the long-term and most people who lose weight regain it over subsequent years. The identification of a non-pharmacological intervention to improve insulin sensitivity in individuals could have a significant impact in an increasingly obese population. We therefore propose to study the effect of 3- month of dietary supplementation with 45-g of slowly digestible starch on risk factors for the development of type 2 diabetes in people with pre-diabetes (IGT). Preliminary data indicate that these starches may influence the gut microbial species which in turn may enhance insulin sensitivity and protect against the development of diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NORC admin supplement
-
批准号:10442246
-
项目类别:
-
资助金额:$3.92万
-
财政年份:2021
-
负责人:Eric Ravussin
-
依托单位:
Pennington/Louisiana NORC - Admin Supplement for Pilot and Feasibility studies 2021
-
批准号:10399166
-
项目类别:
-
资助金额:$14.8万
-
财政年份:2021
-
负责人:Eric Ravussin
-
依托单位:
LAAZ-NPH Clinical Center
-
批准号:10539294
-
项目类别:
-
资助金额:$170.95万
-
财政年份:2021
-
负责人:Eric Ravussin
-
依托单位:
Pennington/Louisiana NORC - Supplement NOT-OD-21-089
-
批准号:10408519
-
项目类别:
-
资助金额:$22.1万
-
财政年份:2021
-
负责人:Eric Ravussin
-
依托单位:
Role of slowly digestible starch in diabetes risk factors in pre-diabetic people
-
批准号:8501442
-
项目类别:
-
资助金额:$47.63万
-
财政年份:2012
-
负责人:Eric Ravussin
-
依托单位:
Role of Slowly Digestible Starch in Diabetes Risk Factors in Pre-Diabetic People
-
批准号:9060311
-
项目类别:
-
资助金额:$48.41万
-
财政年份:2012
-
负责人:Eric Ravussin
-
依托单位:
Role of slowly digestible starch in diabetes risk factors in pre-diabetic people
-
批准号:8668050
-
项目类别:
-
资助金额:$51.83万
-
财政年份:2012
-
负责人:Eric Ravussin
-
依托单位:
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
-
批准号:8666638
-
项目类别:
-
资助金额:$33.03万
-
财政年份:2011
-
负责人:Eric Ravussin
-
依托单位:
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
-
批准号:8440368
-
项目类别:
-
资助金额:$35.88万
-
财政年份:2011
-
负责人:Eric Ravussin
-
依托单位:
Pilot & Feasibility Program
-
批准号:8016486
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2010
-
负责人:Eric Ravussin
-
依托单位:
Research Base
-
批准号:8020226
-
项目类别:
-
资助金额:$7.53万
-
财政年份:2010
-
负责人:Eric Ravussin
-
依托单位:
ADMINISTRATIVE CORE
-
批准号:8016487
-
项目类别:
-
资助金额:$22.57万
-
财政年份:2010
-
负责人:Eric Ravussin
-
依托单位:
CENTER DIRECTOR
-
批准号:8016485
-
项目类别:
-
资助金额:$22.57万
-
财政年份:2010
-
负责人:Eric Ravussin
-
依托单位:
Metabolic Adaptation After 2 Years of Caloric Restriction in Non-Obese Humans
-
批准号:7774360
-
项目类别:
-
资助金额:$21.09万
-
财政年份:2008
-
负责人:Eric Ravussin
-
依托单位:
Metabolic Adaptation After 2 Years of Caloric Restriction in Non-Obese Humans
-
批准号:8092707
-
项目类别:
-
资助金额:$20.07万
-
财政年份:2008
-
负责人:Eric Ravussin
-
依托单位:
Metabolic Adaptation After 2 Years of Caloric Restriction in Non-Obese Humans
-
批准号:7847478
-
项目类别:
-
资助金额:$23.87万
-
财政年份:2008
-
负责人:Eric Ravussin
-
依托单位:
Metabolic Adaptation After 2 Years of Caloric Restriction in Non-Obese Humans
-
批准号:8300834
-
项目类别:
-
资助金额:$22.94万
-
财政年份:2008
-
负责人:Eric Ravussin
-
依托单位:
Metabolic Adaptation After 2 Years of Caloric Restriction in Non-Obese Humans
-
批准号:7525779
-
项目类别:
-
资助金额:$18.33万
-
财政年份:2008
-
负责人:Eric Ravussin
-
依托单位:
Pennington/Louisiana NORC Supplement - 2021 Trans-NORC Training Course in Nutrition and Obesity Research Methods
-
批准号:10187383
-
项目类别:
-
资助金额:$12.32万
-
财政年份:2005
-
负责人:Eric Ravussin
-
依托单位:
Admin Core
-
批准号:10394904
-
项目类别:
-
资助金额:$25.85万
-
财政年份:2005
-
负责人:Eric Ravussin
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: